Topiroxostat (BioDeep_00000772275)
代谢物信息卡片
Topiroxostat
化学式: C13H8N6 (248.081)
中文名称: 托匹司他
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
InChI: InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
描述信息
C471 - Enzyme Inhibitor > C1637 - Xanthine Oxidase Inhibitor
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D09786
- PubChem: 5288320
- DrugBank: DB01685
- ChEMBL: CHEMBL1078685
- CAS: 577778-58-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Young Ho Lee, Gwan Gyu Song. Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
International journal of clinical pharmacology and therapeutics.
2022 Apr; 60(4):176-183. doi:
10.5414/cp204108. [PMID: 34889733] - Takuji Hosoya, Shunya Uchida, Shigeru Shibata, Naoko H Tomioka, Koji Matsumoto, Makoto Hosoyamada. Xanthine Oxidoreductase Inhibitors Suppress the Onset of Exercise-Induced AKI in High HPRT Activity Urat1-Uox Double Knockout Mice.
Journal of the American Society of Nephrology : JASN.
2022 02; 33(2):326-341. doi:
10.1681/asn.2021050616. [PMID: 34799437] - Masashi Sakuma, Shigeru Toyoda, Takuo Arikawa, Yota Koyabu, Toru Kato, Taichi Adachi, Hideaki Suwa, Jun-Ichi Narita, Koetsu Anraku, Kimihiko Ishimura, Fumitake Yamauchi, Yasunori Sato, Teruo Inoue. Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
PloS one.
2022 ; 17(1):e0261445. doi:
10.1371/journal.pone.0261445. [PMID: 35077456] - Kazuhisa Takahashi, Hiroki Mizukami, Sho Osonoi, Saori Ogasawara, Yutaro Hara, Kazuhiro Kudoh, Yuki Takeuchi, Takanori Sasaki, Makoto Daimon, Soroku Yagihashi. Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.
Neurobiology of disease.
2021 07; 155(?):105392. doi:
10.1016/j.nbd.2021.105392. [PMID: 34000416] - Takashi Nakamura, Mai Nampei, Takayo Murase, Etsuko Satoh, Seigo Akari, Noriaki Katoh, Hiroki Mizukami. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
Nutrition & diabetes.
2021 04; 11(1):12. doi:
10.1038/s41387-021-00155-2. [PMID: 33850106] - Kazuomi Kario, Masafumi Nishizawa, Mari Kiuchi, Arihiro Kiyosue, Fumishi Tomita, Hiroshi Ohtani, Yasuhisa Abe, Hideyo Kuga, Satoshi Miyazaki, Takatoshi Kasai, Makiko Hongou, Takanori Yasu, Jin Kuramochi, Yoshihiro Fukumoto, Satoshi Hoshide, Ichiro Hisatome. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Journal of clinical hypertension (Greenwich, Conn.).
2021 02; 23(2):334-344. doi:
10.1111/jch.14153. [PMID: 33400348] - Arrigo F G Cicero, Federica Fogacci, Raffaele Ivan Cincione, Giuliano Tocci, Claudio Borghi. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre.
2021; 30(2):122-130. doi:
10.1159/000512178. [PMID: 33040063] - Xiangling Feng, Yan Cao, Yufeng Ding, Heng Zheng. Development and validation for the quantitative determination of xanthine oxidoreductase inhibitor topiroxostat by LC-MS/MS and its clinico-pharmacokinetic study.
Journal of pharmaceutical and biomedical analysis.
2020 Sep; 189(?):113470. doi:
10.1016/j.jpba.2020.113470. [PMID: 32795880] - Tomohiko Ishikawa, Tatsushi Maeda, Teruo Hashimoto, Tetsuya Nakagawa, Kazuhito Ichikawa, Yasushi Sato, Yoshihiko Kanno. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
Clinical drug investigation.
2020 Sep; 40(9):847-859. doi:
10.1007/s40261-020-00941-3. [PMID: 32621143] - Akira Sezai, Satoshi Unosawa, Makoto Taoka, Shunji Osaka, Hisakuni Sekino, Masashi Tanaka. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
2020 Aug; 26(4):202-208. doi:
10.5761/atcs.oa.19-00162. [PMID: 31748427] - Hiroshi Matsuo, Eiji Ishikawa, Hirofumi Machida, Yasuhide Mizutani, Akiko Tanoue, Takahiro Ohnishi, Tomohiro Murata, Shinya Okamoto, Toru Ogura, Yuki Nishimura, Hiroo Ito, Masashi Yasutomi, Kan Katayama, Shinsuke Nomura, Masaaki Ito. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Clinical and experimental nephrology.
2020 Apr; 24(4):307-313. doi:
10.1007/s10157-019-01829-z. [PMID: 31845065] - Masato Kasahara, Yoshihiro Kuwabara, Toshiki Moriyama, Kazuaki Tanabe, Noriko Satoh-Asahara, Tomohiro Katsuya, Shinya Hiramitsu, Hidetaka Shimada, Tosiya Sato, Yoshihiko Saito, Takahiko Nakagawa. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial.
Clinical and experimental nephrology.
2020 Mar; 24(3):235-241. doi:
10.1007/s10157-019-01815-5. [PMID: 31729647] - Daisuke Okui, Tomomitsu Sasaki, Masahiko Fushimi, Tetsuo Ohashi. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Clinical and experimental nephrology.
2020 Mar; 24(Suppl 1):92-102. doi:
10.1007/s10157-019-01817-3. [PMID: 31734820] - Hiroshi Arakawa, Natsumi Amezawa, Yu Kawakatsu, Ikumi Tamai. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
Biological & pharmaceutical bulletin.
2020; 43(11):1792-1798. doi:
10.1248/bpb.b20-00597. [PMID: 33132325] - Zhiqiang Luo, Guohua Yu, Xing Han, Tingting Yang, Yanhua Ji, Huating Huang, Guopeng Wang, Yang Liu, Wenyan Sun. Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Jan; 121(?):109660. doi:
10.1016/j.biopha.2019.109660. [PMID: 31733581] - Shingo Higa, Daisuke Shima, Naoko Tomitani, Yoko Fujimoto, Kazuomi Kario. The effects of topiroxostat on vascular function in patients with hyperuricemia.
Journal of clinical hypertension (Greenwich, Conn.).
2019 11; 21(11):1713-1720. doi:
10.1111/jch.13707. [PMID: 31556223] - Shuichi Tohyo. Topiroxostat influences circulating lipid concentrations in hyperuricemic patients
.
International journal of clinical pharmacology and therapeutics.
2019 Nov; 57(11):567-570. doi:
10.5414/cp203478. [PMID: 31496508] - Xinrui Li, Jing Liu, Liang Ma, Ping Fu. Pharmacological urate-lowering approaches in chronic kidney disease.
European journal of medicinal chemistry.
2019 Mar; 166(?):186-196. doi:
10.1016/j.ejmech.2019.01.043. [PMID: 30769179] - Masashi Sakuma, Shigeru Toyoda, Takuo Arikawa, Yota Koyabu, Toru Kato, Taichi Adachi, Hideaki Suwa, Jun-Ichi Narita, Koetsu Anraku, Kimihiko Ishimura, Fumitake Yamauchi, Yasunori Sato, Teruo Inoue. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Clinical and experimental nephrology.
2018 Dec; 22(6):1379-1386. doi:
10.1007/s10157-018-1599-6. [PMID: 29916098] - Tatsuo Hosoya, Tomohiko Ishikawa, Yoshimi Ogawa, Ryusuke Sakamoto, Tetsuo Ohashi. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
Clinical drug investigation.
2018 Dec; 38(12):1135-1143. doi:
10.1007/s40261-018-0699-0. [PMID: 30219951] - Toshihiro Mizukoshi, Sawako Kato, Masahiko Ando, Hiroshi Sobajima, Norimi Ohashi, Tomohiko Naruse, Yosuke Saka, Hideaki Shimizu, Takanobu Nagata, Shoichi Maruyama. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial.
Nephrology (Carlton, Vic.).
2018 Nov; 23(11):1023-1030. doi:
10.1111/nep.13177. [PMID: 28990729] - Takashi Wada, Tatsuo Hosoya, Daisuke Honda, Ryusuke Sakamoto, Kazutaka Narita, Tomomitsu Sasaki, Daisuke Okui, Kenjiro Kimura. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).
Clinical and experimental nephrology.
2018 Aug; 22(4):860-870. doi:
10.1007/s10157-018-1530-1. [PMID: 29372470] - Yume Nagaoka, Yoshiko Tanaka, Hiroshi Yoshimoto, Rie Suzuki, Kakei Ryu, Mio Ueda, Minako Akiyama, Miho Nagai, Yoshitaka Miyaoka, Eiichiro Kanda, Shinnichi Iwai, Michio Nagaoka, Yoshihiko Kanno. The effect of small dose of topiroxostat on serum uric acid in patients receiving hemodialysis.
Hemodialysis international. International Symposium on Home Hemodialysis.
2018 07; 22(3):388-393. doi:
10.1111/hdi.12620. [PMID: 29227568] - Taro Horino, Yutaka Hatakeyama, Osamu Ichii, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Yoshio Terada, Yoshiyasu Okuhara. Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.
Clinical and experimental nephrology.
2018 Apr; 22(2):337-345. doi:
10.1007/s10157-017-1452-3. [PMID: 28752287] - Shunya Uchida, Takanori Kumagai, Wen Xiu Chang, Yoshifuru Tamura, Shigeru Shibata. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Contributions to nephrology.
2018; 192(?):56-68. doi:
10.1159/000484279. [PMID: 29393121] - Keiichi Ohata, Atsuko Kamijo-Ikemori, Takeshi Sugaya, Chihiro Hibi, Takashi Nakamura, Takayo Murase, Tsuyoshi Oikawa, Seiko Hoshino, Kimie Katayama, Junko Asano, Kenjiro Kimura, Yugo Shibagaki. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression.
European journal of pharmacology.
2017 Nov; 815(?):88-97. doi:
10.1016/j.ejphar.2017.09.005. [PMID: 28888756] - Anna Pisano, Valeria Cernaro, Guido Gembillo, Graziella D'Arrigo, Michele Buemi, Davide Bolignano. Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
International journal of molecular sciences.
2017 Oct; 18(11):. doi:
10.3390/ijms18112283. [PMID: 29088122] - Akira Sezai, Kazuaki Obata, Keisuke Abe, Sakie Kanno, Hisakuni Sekino. Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Circulation journal : official journal of the Japanese Circulation Society.
2017 Oct; 81(11):1707-1712. doi:
10.1253/circj.cj-17-0438. [PMID: 28603225] - Yosuke Kawamorita, Takeshi Shiraishi, Yoshifuru Tamura, Takanori Kumagai, Shigeru Shibata, Yoshihide Fujigaki, Makoto Hosoyamada, Takahiko Nakagawa, Shunya Uchida. Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats.
Physiological reports.
2017 Aug; 5(15):. doi:
10.14814/phy2.13358. [PMID: 28774949] - Hiroyuki Terawaki, Hokuto Hoshi, Junichiro James Kazama. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Clinical and experimental nephrology.
2017 04; 21(2):356-357. doi:
10.1007/s10157-017-1388-7. [PMID: 28247173] - Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Koichi Node. Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report.
Drugs in R&D.
2017 Mar; 17(1):97-101. doi:
10.1007/s40268-016-0169-1. [PMID: 28074335] - Tatsuo Hosoya, Tomomitsu Sasaki, Tetsuo Ohashi. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Clinical rheumatology.
2017 Mar; 36(3):649-656. doi:
10.1007/s10067-016-3474-8. [PMID: 27832384] - Satoru Mitsuboshi, Hitoshi Yamada, Kazuhiko Nagai, Hideo Okajima. Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Biological & pharmaceutical bulletin.
2017; 40(9):1463-1467. doi:
10.1248/bpb.b17-00284. [PMID: 28867729] - Takashi Nakamura, Takayo Murase, Mai Nampei, Nobutaka Morimoto, Naoki Ashizawa, Takashi Iwanaga, Ryusuke Sakamoto. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
European journal of pharmacology.
2016 Jun; 780(?):224-31. doi:
10.1016/j.ejphar.2016.03.055. [PMID: 27038523] - Atsuko Kamijo-Ikemori, Takeshi Sugaya, Chihiro Hibi, Takashi Nakamura, Takayo Murase, Tsuyoshi Oikawa, Seiko Hoshino, Mikako Hisamichi, Kazuaki Hirata, Kenjiro Kimura, Yugo Shibagaki. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
American journal of physiology. Renal physiology.
2016 06; 310(11):F1366-76. doi:
10.1152/ajprenal.00517.2015. [PMID: 27029427] - T Hosoya, Y Ogawa, H Hashimoto, T Ohashi, R Sakamoto. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Journal of clinical pharmacy and therapeutics.
2016 Jun; 41(3):290-7. doi:
10.1111/jcpt.12391. [PMID: 27109450] - T Hosoya, T Sasaki, H Hashimoto, R Sakamoto, T Ohashi. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
Journal of clinical pharmacy and therapeutics.
2016 Jun; 41(3):298-305. doi:
10.1111/jcpt.12392. [PMID: 27079434] - Sawako Kato, Masahiko Ando, Toshihiro Mizukoshi, Takanobu Nagata, Takayuki Katsuno, Tomoki Kosugi, Naotake Tsuboi, Shoichi Maruyama. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Nagoya journal of medical science.
2016 05; 78(2):135-42. doi:
NULL. [PMID: 27303100] - Tetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga, Kazuhiro Saitoh. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
The Journal of pharmacy and pharmacology.
2016 Jan; 68(1):76-83. doi:
10.1111/jphp.12490. [PMID: 26589240] - Sulistiyati Bayu Utami, Endang Mahati, Peili Li, Nani Maharani, Nobuhito Ikeda, Udin Bahrudin, Chishio Munemura, Makoto Hosoyamada, Yasutaka Yamamoto, Akio Yoshida, Yuji Nakayama, Katsumi Higaki, Eiji Nanba, Haruaki Ninomiya, Yasuaki Shirayoshi, Kimiyoshi Ichida, Kazuhiro Yamamoto, Tatsuo Hosoya, Ichiro Hisatome. Apoptosis induced by an uromodulin mutant C112Y and its suppression by topiroxostat.
Clinical and experimental nephrology.
2015 Aug; 19(4):576-84. doi:
10.1007/s10157-014-1032-8. [PMID: 25239792] - Tatsuo Hosoya, Iwao Ohno, Shinsuke Nomura, Ichiro Hisatome, Shunya Uchida, Shin Fujimori, Tetsuya Yamamoto, Shigeko Hara. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Clinical and experimental nephrology.
2014 Dec; 18(6):876-84. doi:
10.1007/s10157-014-0935-8. [PMID: 24448692] - Takeo Shimo, Mitsuyoshi Moto, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga, Kazuhiro Saito. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors.
Archives of toxicology.
2014 Apr; 88(4):1035-42. doi:
10.1007/s00204-014-1195-9. [PMID: 24448833] - Takeo Shimo, Naoki Ashizawa, Mitsuyoshi Moto, Takashi Iwanaga, Osamu Nagata. Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Archives of toxicology.
2011 May; 85(5):505-12. doi:
10.1007/s00204-010-0598-5. [PMID: 20936465] - Takeo Shimo, Mitsuyoshi Moto, Naoki Ashizawa, Kazuhiko Oba, Osamu Nagata. Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Drug and chemical toxicology.
2011 Apr; 34(2):192-8. doi:
10.3109/01480545.2010.500291. [PMID: 21314469] - Naoki Ashizawa, Takeo Shimo, Koji Matsumoto, Tetsuya Taniguchi, Mitsuyoshi Moto, Osamu Nagata. Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Drug and chemical toxicology.
2011 Apr; 34(2):151-61. doi:
10.3109/01480545.2010.494667. [PMID: 21105859] - Takahiro Sato, Naoki Ashizawa, Koji Matsumoto, Takashi Iwanaga, Hiroshi Nakamura, Tsutomu Inoue, Osamu Nagata. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Bioorganic & medicinal chemistry letters.
2009 Nov; 19(21):6225-9. doi:
10.1016/j.bmcl.2009.08.091. [PMID: 19783139] - Takeo Shimo, Naoki Ashizawa, Mitsuyoshi Moto, Koji Matsumoto, Takashi Iwanaga, Osamu Nagata. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.
Toxicologic pathology.
2009 Jun; 37(4):438-45. doi:
10.1177/0192623309332995. [PMID: 19336671] - Koichi Omura, Takashi Nakazawa, Takahiro Sato, Takashi Iwanaga, Osamu Nagata. Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Dec; 35(12):2143-8. doi:
10.1124/dmd.107.017251. [PMID: 17761779] - Naoki Ashizawa, Takeo Shimo, Koji Matsumoto, Kazuhiko Oba, Takashi Nakazawa, Osamu Nagata. Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Toxicology and applied pharmacology.
2006 Dec; 217(3):260-5. doi:
10.1016/j.taap.2006.09.015. [PMID: 17084874] - Takashi Nakazawa, Kengo Miyata, Koichi Omura, Takashi Iwanaga, Osamu Nagata. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Drug metabolism and disposition: the biological fate of chemicals.
2006 Nov; 34(11):1880-6. doi:
10.1124/dmd.106.011692. [PMID: 16914512] - Takeo Shimo, Naoki Ashizawa, Koji Matsumoto, Takashi Nakazawa, Osamu Nagata. Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Toxicological sciences : an official journal of the Society of Toxicology.
2005 Sep; 87(1):267-76. doi:
10.1093/toxsci/kfi210. [PMID: 15933230]
